Ipraterol-Nativ solution for ing 0.25 + 0.5 mg 20 ml
Condition: New product
1000 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Ipratropium bromide + Fenoterol
Release form
Solution
Composition
1 ml ipratropium bromide monohydrate 0.261 mg, which corresponds to the content of ipratropium bromide 0.25 mg fenoterol hydrobromide 0.5 mg.
Pharmacological effect
Ipraterol-native contains two components with bronchodilator activity: ipratropium bromide - m-holinoblokator and fenoterol - adrenergic mimic. Bronchodilatation with inhalation ipratropium bromide is mainly due to local rather than systemic anticholinergic effects. In patients with bronchospasm associated with chronic obstructive pulmonary diseases (chronic bronchitis and pulmonary emphysema), a significant improvement in lung function (an increase in FEV1 and PSV by 15% or more) was noted within 15 minutes, the maximum effect was achieved in 1-2 hours and lasted in most patients up to 6 hours after administration. Ipratropium bromide does not adversely affect the secretion of mucus in the respiratory tract, mucociliary clearance and gas exchange. Fenoterol selectively stimulates & # 946 .2-adrenergic receptors in a therapeutic dose. Stimulation of & # 946 .2-adrenoreceptors occurs when using high doses. Fenoterol relaxes the smooth muscles of the bronchi and blood vessels and counteracts the development of bronchospastic reactions caused by the effect of histamine, methacholine, cold air and allergens (immediate type hypersensitivity reactions). Immediately after the administration, fenoterol blocks the release of inflammatory and broncho-obstructive mediators from mast cells. In addition, when using fenoterol in higher doses, there was an increase in mucociliary clearance. The beta-adrenergic effect of the drug on cardiac activity, such as an increase in the frequency and strength of heart contractions, is due to the vascular action of fenoterol, stimulation of the heart and, when using doses exceeding therapeutic, stimulation. As with other beta-adrenergic drugs, the QTC interval was lengthened with high doses. The clinical significance of this manifestation is not clarified. Tremor is the most common undesirable effect when using beta-adrenoreceptor agonies.With the combined use of these two active substances, the bronchodilator effect is achieved by exposing various pharmacological targets. These substances complement each other, as a result, the antispasmodic effect on the muscles of the bronchi is enhanced and the breadth of the therapeutic effect in case of bronchopulmonary diseases accompanied by constriction of the respiratory tract is ensured. The complementary effect is such that to achieve the desired effect, a lower dose of the beta-adrenergic component is required, which allows you to individually select an effective dose with almost no side effects.
Indications
- prevention and symptomatic treatment of chronic obstructive respiratory diseases with reversible airway obstruction, such as bronchial asthma and, especially, chronic obstructive pulmonary disease, chronic obstructive bronchitis with or without emphysema.
Contraindications
- hypersensitivity to fenoterol or atropine-like drugs or other components of the drug Ipraterol-native - hypertrophic obstructive cardiomyopathy - tachyarrhythmia - I and III trimesters of pregnancy. With care: angle-closure glaucoma, arterial hypertension, diabetes mellitus, recent myocardial infarction (within the last 3 months), cardiovascular diseases such as chronic heart failure, ischemic heart disease, aortic stenosis, marked cerebral and peripheral arteries, hyperthyroidism , pheochromocytoma, prostatic hyperplasia, bladder neck obstruction, cystic fibrosis, II trimester of pregnancy, breastfeeding, children under 6 years old.
Use during pregnancy and lactation
The data of preclinical studies and experience with the combination of ipratropium bromide and fenoterol show that the components of the drug do not have a negative effect during pregnancy. The possibility of an inhibitory effect of fenoterol on the contractile activity of the uterus should be considered. The drug is contraindicated in the I and III trimesters of pregnancy (the possibility of weakening the labor activity of fenoterol). It should be used with caution in the II trimester of pregnancy. Fenoterol passes into breast milk.Data confirming that ipratropium bromide penetrates into breast milk has not been obtained. However, the drug Ipraterol-native should be used with caution in nursing mothers.
Side effects
Frequency determination: very often (> 1/10), often (from 1/100 to 1/10), infrequently (from 1/1000 to 1/100), rarely (from 1/10000 to 1/000), very rare (1/10000). On the part of the nervous system: often - minor tremor of skeletal muscles, nervousness. rarely - headache, dizziness, very rarely - a change in the psyche. Since the cardiovascular system: often - tachycardia, including supraventricular tachycardia. feeling of heartbeat (especially in patients with aggravating factors). rarely (when used in high doses) - a decrease in diastolic blood pressure, an increase in systolic blood pressure, arrhythmia (including atrial fibrillation). On the part of the respiratory system: rarely - cough, local irritation of the airways, pharyngitis. very rarely paradoxical bronchospasm, laryngism. On the part of the digestive tract: often - dry mouth. infrequently, gastrointestinal dysmotility, vomiting, constipation, diarrhea (especially in patients with cystic fibrosis). On the part of the organ of vision: if the drug gets into the eye, mydriasis, increased intraocular pressure, glaucoma, pain in the eyeball. sometimes with drug treatment there are reversible disturbances of accommodation and glaucoma. Pain in the eyeball or discomfort, blurred vision, feeling of appearance of halo or color spots before the eyes, in combination with conjunctival hyperemia and corneal edema can be symptoms of acute glaucoma. Pupillary constriction should be used and immediately contact an ophthalmologist. Allergic reactions: rarely - skin rash, angioedema of the tongue, lips and face, urticaria. Other: urinary retention, increased sweating, hypokalemia, feeling of general weakness, myalgia.
special instructions
Frequency determination: very often (> 1/10), often (from 1/100 to 1/10), infrequently (from 1/1000 to 1/100), rarely (from 1/10000 to 1/000), very rare (1/10000). On the part of the nervous system: often - minor tremor of skeletal muscles, nervousness. rarely - headache, dizziness, very rarely - a change in the psyche. Since the cardiovascular system: often - tachycardia, including supraventricular tachycardia. feeling of heartbeat (especially in patients with aggravating factors). rarely (when used in high doses) - a decrease in diastolic blood pressure, an increase in systolic blood pressure, arrhythmia (including atrial fibrillation).On the part of the respiratory system: rarely - cough, local irritation of the airways, pharyngitis. very rarely paradoxical bronchospasm, laryngism. On the part of the digestive tract: often - dry mouth. infrequently, gastrointestinal dysmotility, vomiting, constipation, diarrhea (especially in patients with cystic fibrosis). On the part of the organ of vision: if the drug gets into the eye, mydriasis, increased intraocular pressure, glaucoma, pain in the eyeball. sometimes with drug treatment there are reversible disturbances of accommodation and glaucoma. Pain in the eyeball or discomfort, blurred vision, feeling of appearance of halo or color spots before the eyes, in combination with conjunctival hyperemia and corneal edema can be symptoms of acute glaucoma. Pupillary constriction should be used and immediately contact an ophthalmologist. Allergic reactions: rarely - skin rash, angioedema of the tongue, lips and face, urticaria. Other: urinary retention, increased sweating, hypokalemia, feeling of general weakness, myalgia.